Possible marker for recurring HPV-linked oropharyngeal cancers
Source: www.eureka.orgAuthor: John Hopkins Media Contact: Vanessa Wasta A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at The Johns Hopkins University. A report on the study is published in the February issue of Cancer Prevention Research. HPV infections, which are virtually all sexually transmitted, are responsible for the recent rise in the incidence of oropharyngeal cancers in the United States, according to the National Cancer Institute, and now account for about 80 percent of these cancers. People with HPV-positive tumors of the throat, base of the tongue and tonsils have higher overall survival rates compared to people with similar tumors not caused by HPV, but studies show that more than 25 percent of HPV-positive cancers recur--usually within the first two years after treatment. "There are currently no reliable tests available to detect early recurrence, so we hope to find a biological marker that could help identify those most at risk," says Carole Fakhry, M.D., M.P.H., associate professor of otolaryngology-head and neck surgery at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center. For the new study, Fakhry and her colleagues focused their attention on the antibodies, or immune system protein the body produces to fight HPV-related cancer proteins. One such antibody, called E6, is strongly linked to the diagnosis [...]